Evidence map›Paper›PMID 28928954›Full record

ReviewF1000Research2017

Rotavirus Vaccines: a story of success with challenges ahead.

Miguel O'Ryan

Open access · goldAbstract readReview
In one paragraph

Review in F1000Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Effectiveness of RotarixWellcome open research · 2020
    Pooled it
  2. Birth Cohort Studies Assessing Norovirus Infection and Immunity in Young Children: A Review.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Vaccines · 2023
    Article
  8. Article
  9. Article
  10. The Complex Interactions Between Rotavirus and the Gut Microbiota.Frontiers in cellular and infection microbiology · 2020
    Review
  11. Article
  12. Article
  13. mSphere
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Miguel O'RyanInstitute of Biomedical Sciences and Millenium Institute of Immunology and Immunotherapy, Faculty of Medicine, University of Chile, Santiago, Chile.
Millennium Institute on Immunology and Immunotherapy · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Approximately 40 years have passed since the discovery of the rotavirus and 10 years since the introduction and progressive dissemination of rotavirus vaccines worldwide. Currently, 92 countries have introduced rotavirus vaccines into national or subnational programs with evident impact in disease reduction. Two vaccines have been widely used, and four additional vaccines have been licensed and are being used in defined regions. In this context, one main issue that remains unsolved is the lower vaccine efficacy/effectiveness in low-income countries. An additional partially answered issue relates to rotavirus strain circulation in vaccinated populations. These issues are discussed in this review. The most imperative challenge ahead is to fulfill the WHO's recommendation to introduce rotavirus vaccines in all countries.

Indexed as

gastroenteritisimmunityrotavirusvaccination

Identifiers

PMID28928954
PMCPMC5580433
OpenAlexW2747541229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.